Is DARE or ACRV more profitable?

Dare Bioscience's return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media favor DARE or ACRV?

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 5 mentions for Acrivon Therapeutics and 4 mentions for Dare Bioscience. Acrivon Therapeutics' average media sentiment score of 0.98 beat Dare Bioscience's score of 0.56 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acrivon Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, DARE or CLNN?

Dare Bioscience has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 18.74 -$13.40M -$0.95 N/A Clene $200K 344.42 -$26.17M -$3.20 N/A

Is DARE or CLNN more profitable?

Dare Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Clene -25,009.70% N/A -137.98%

Does the media prefer DARE or CLNN?

In the previous week, Dare Bioscience had 2 more articles in the media than Clene. MarketBeat recorded 4 mentions for Dare Bioscience and 2 mentions for Clene. Clene's average media sentiment score of 0.93 beat Dare Bioscience's score of 0.56 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate DARE or TELO?

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 681.25%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is DARE or TELO more profitable?

Dare Bioscience's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media favor DARE or TELO?

In the previous week, Dare Bioscience had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Dare Bioscience and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat Dare Bioscience's score of 0.56 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIFC or DARE?

Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 681.25%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, AIFC or DARE?

Dare Bioscience has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 2.44 -$344.51M N/A N/A Dare Bioscience $1.03M 18.74 -$13.40M -$0.95 N/A

Which has stronger valuation and earnings, DARE or IBIO?

Dare Bioscience has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 18.74 -$13.40M -$0.95 N/A iBio $400K 177.61 -$18.38M -$0.58 N/A

Is DARE or IBIO more profitable?

Dare Bioscience's return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% iBio N/A -53.86% -46.48%

Does the media favor DARE or IBIO?

In the previous week, Dare Bioscience had 2 more articles in the media than iBio. MarketBeat recorded 4 mentions for Dare Bioscience and 2 mentions for iBio. iBio's average media sentiment score of 1.86 beat Dare Bioscience's score of 0.56 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Dare Bioscience (DARE) Competitors

$1.28 +0.02 (+1.59%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.25 -0.03 (-2.34%)

As of 07/24/2026 05:55 PM Eastern

Compare

DARE vs. ACRV, CLNN, TELO, AIFC, and IBIO

Should you buy Dare Bioscience stock or one of its competitors? MarketBeat compares Dare Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dare Bioscience include Acrivon Therapeutics (ACRV), Clene (CLNN), Telomir Pharmaceuticals (TELO), ALT5 Sigma (AIFC), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry.

How does Dare Bioscience compare to Acrivon Therapeutics?

Dare Bioscience (NASDAQ:DARE) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 5 mentions for Acrivon Therapeutics and 4 mentions for Dare Bioscience. Acrivon Therapeutics' average media sentiment score of 0.98 beat Dare Bioscience's score of 0.56 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience currently has a consensus target price of $10.00, indicating a potential upside of 681.25%. Acrivon Therapeutics has a consensus target price of $11.67, indicating a potential upside of 629.17%. Given Dare Bioscience's higher possible upside, equities research analysts clearly believe Dare Bioscience is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Dare Bioscience's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Dare Bioscience has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market.

Dare Bioscience has higher revenue and earnings than Acrivon Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	18.74	-$13.40M	-$0.95	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Dare Bioscience on 8 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Clene?

Dare Bioscience (NASDAQ:DARE) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Dare Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Clene	-25,009.70%	N/A	-137.98%

Dare Bioscience has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	18.74	-$13.40M	-$0.95	N/A
Clene	$200K	344.42	-$26.17M	-$3.20	N/A

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dare Bioscience currently has a consensus target price of $10.00, suggesting a potential upside of 681.25%. Clene has a consensus target price of $33.25, suggesting a potential upside of 516.88%. Given Dare Bioscience's higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Dare Bioscience had 2 more articles in the media than Clene. MarketBeat recorded 4 mentions for Dare Bioscience and 2 mentions for Clene. Clene's average media sentiment score of 0.93 beat Dare Bioscience's score of 0.56 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Clene has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Summary

Dare Bioscience beats Clene on 9 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Telomir Pharmaceuticals?

Dare Bioscience (NASDAQ:DARE) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Dare Bioscience has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

In the previous week, Dare Bioscience had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Dare Bioscience and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat Dare Bioscience's score of 0.56 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 681.25%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.7% of Dare Bioscience shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dare Bioscience's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Dare Bioscience. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	18.74	-$13.40M	-$0.95	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Summary

Dare Bioscience beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Dare Bioscience compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Dare Bioscience (NASDAQ:DARE) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Dare Bioscience has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	2.44	-$344.51M	N/A	N/A
Dare Bioscience	$1.03M	18.74	-$13.40M	-$0.95	N/A

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ALT5 Sigma has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

In the previous week, Dare Bioscience had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Dare Bioscience and 1 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.94 beat Dare Bioscience's score of 0.56 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Overall Sentiment
ALT5 Sigma	Positive
Dare Bioscience	Positive

Dare Bioscience has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Dare Bioscience's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Dare Bioscience	N/A	N/A	-46.22%

Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 681.25%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Dare Bioscience beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to iBio?

Dare Bioscience (NASDAQ:DARE) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Dare Bioscience has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, iBio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 681.25%. iBio has a consensus target price of $5.00, indicating a potential upside of 249.65%. Given Dare Bioscience's higher probable upside, analysts clearly believe Dare Bioscience is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

In the previous week, Dare Bioscience had 2 more articles in the media than iBio. MarketBeat recorded 4 mentions for Dare Bioscience and 2 mentions for iBio. iBio's average media sentiment score of 1.86 beat Dare Bioscience's score of 0.56 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Dare Bioscience has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	18.74	-$13.40M	-$0.95	N/A
iBio	$400K	177.61	-$18.38M	-$0.58	N/A

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dare Bioscience's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
iBio	N/A	-53.86%	-46.48%

Summary

iBio beats Dare Bioscience on 8 of the 15 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.30M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.35	21.48	27.14	23.64
Price / Sales	18.74	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	6.40	7.88	10.28	6.07
Net Income	-$13.40M	$23.86M	$3.60B	$331.99M
7 Day Performance	-34.69%	-3.82%	-1.27%	-0.63%
1 Month Performance	-36.00%	-2.61%	-0.37%	-2.00%
1 Year Performance	-50.19%	32.79%	18.30%	13.62%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.8829 of 5 stars	$1.28 +1.6%	$10.00 +681.3%	-51.3%	$19.30M	$1.03M	N/A	30
ACRV Acrivon Therapeutics	3.8531 of 5 stars	$1.75 +0.6%	$11.67 +566.7%	+15.1%	$74.90M	N/A	N/A	58	News Coverage Short Interest Decrease
CLNN Clene	3.1667 of 5 stars	$5.85 +2.1%	$33.25 +468.4%	+47.3%	$74.76M	$200K	N/A	100
TELO Telomir Pharmaceuticals	0.4536 of 5 stars	$1.08 +17.5%	N/A	-49.8%	$74.28M	N/A	N/A	1	Positive News
AIFC ALT5 Sigma	0.4296 of 5 stars	$0.51 -10.1%	N/A	-93.9%	$71.40M	$24.84M	N/A	170	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. ACRV, CLNN, TELO, AIFC, and IBIO

How does Dare Bioscience compare to Acrivon Therapeutics?

Summary

How does Dare Bioscience compare to Clene?

Summary

How does Dare Bioscience compare to Telomir Pharmaceuticals?

Summary

How does Dare Bioscience compare to ALT5 Sigma?

Summary

How does Dare Bioscience compare to iBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. ACRV, CLNN, TELO, AIFC, and IBIO

How does Dare Bioscience compare to Acrivon Therapeutics?

Does the media favor DARE or ACRV?

Do analysts rate DARE or ACRV?

Is DARE or ACRV more profitable?

Which has more risk & volatility, DARE or ACRV?

Which has preferable valuation and earnings, DARE or ACRV?

Do insiders and institutionals believe in DARE or ACRV?

Summary

How does Dare Bioscience compare to Clene?

Is DARE or CLNN more profitable?

Which has better earnings and valuation, DARE or CLNN?

Do institutionals and insiders hold more shares of DARE or CLNN?

Do analysts recommend DARE or CLNN?

Does the media prefer DARE or CLNN?

Which has more volatility and risk, DARE or CLNN?

Summary

How does Dare Bioscience compare to Telomir Pharmaceuticals?

Which has more volatility & risk, DARE or TELO?

Does the media favor DARE or TELO?

Do analysts rate DARE or TELO?

Do insiders and institutionals hold more shares of DARE or TELO?

Is DARE or TELO more profitable?

Which has preferable valuation and earnings, DARE or TELO?

Summary

How does Dare Bioscience compare to ALT5 Sigma?

Which has better earnings & valuation, AIFC or DARE?

Do insiders and institutionals hold more shares of AIFC or DARE?

Which has more risk & volatility, AIFC or DARE?

Does the media refer more to AIFC or DARE?

Is AIFC or DARE more profitable?

Do analysts recommend AIFC or DARE?

Summary

How does Dare Bioscience compare to iBio?

Which has more risk and volatility, DARE or IBIO?

Do analysts recommend DARE or IBIO?

Does the media favor DARE or IBIO?

Which has stronger valuation and earnings, DARE or IBIO?

Do institutionals & insiders have more ownership in DARE or IBIO?

Is DARE or IBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools